沈阳市哪家治风疹团医院较好(沈阳治疗毛囊炎哪里医院好) (今日更新中)

When legendary singer Aretha Franklin died, she did not have a will or trust. Her four sons have filed a document listing themselves as interested parties, reports say.Franklin died last week from advanced pancreatic cancer. She was 76.In addition to her sons' filing, Franklin's niece has asked the court to appoint her as a personal representative of the estate, the Detroit Free Press reported. It said under Michigan law, if an unmarried person dies without a will, his or her assets are divided equally among any children.Franklin's lawyer has represented her in entertainment matters for nearly three decades, and told the paper that he constantly asked her to do a trust, but she never got around to it."I was after her for a number of years to do a trust," Los Angeles attorney Don Wilson told the paper. "It would have expedited things and kept them out of probate and kept things private."Wilson is Franklin's attorney in copyright matters, song publishing and record deals, and will be consulted on estate planning purposes. He said while he doesn't have a dollar figure on the value of her assets, the lack of a will means the finances will become public in Oakland County Probate Court."I just hope (Franklin's estate) doesn't end up getting so hotly contested," Wilson said. "Any time they don't leave a trust or will, there always ends up being a fight."CNN has reached out to Wilson for more details.Franklin's funeral will be held on August 31 in Detroit, with the service for family and friends planned for 10 a.m. ET the same day.Public viewings will be held August 28 and 29 from 9 a.m. to 9 p.m. at the Charles H. Wright Museum of African American History in Detroit.Franklin will be entombed at Woodlawn Cemetery in Detroit.The-CNN-Wire 1767

With most Kindergarten through grade 12 schools starting in less than a month, many parents are trying to figure out what is best for their family when given the option between in-person or virtual learning?What about preschool for 3 to 5-year-olds who were looking forward to in-person learning this fall?For parents who believe it’s safer to keep their child home, there are ways to get them learning beyond the A, B, C’s.“With our younger children we know they really thrive in predictability and routine and that is all gone right now,” said parenting expert Carly Dorogi.Preschool participation has fallen by half during the pandemic, according to the National Institute for Early Education Research. But that doesn’t mean kids can’t learn at home.Dorogi says children ages 3 to 5 can learn math using everyday items.“If I have five Cheerios on the table this is what five looks like and it’s a small amount compared to when I have ten Cheerios on the table,” Dorogi said.Playing with dolls or action figures can help language skills, forcing children to talk and put sentences together. Playtime is motor skills time.“Our little guys can actually improve their handwriting by playing with play dough or doing anything that’s a small motor that strengthens their hand muscles,” Dorogi said.If you want to introduce virtual learning, Dorogi suggests Osmo’s starter kit. It’s an app and hands-on play.If you’re looking for workbooks, check out Grand Haven-Based School Zone Publishing. They say their preschool-aged items have been selling more now due to the pandemic. And they have an app called Anywhere Teacher that has a curriculum to follow.Barbara Peacock is the managing director of School Zone Publishing.“What they need to learn first, then next and it’s a step by step program so it’s really nice to kind of tie the two together both print material, doing flashcards, working on worksheets and then putting them for 30-minutes a day on Anywhere Teacher and working with them,” she said.It is OK if your preschooler can’t sit still.“They need to move," Dorogi explained. "Sitting at a desk for even an hour is too much and I don’t want parents to feel like that’s the expectation. So, think about alternative seating. If your child learns best laying on the floor or sitting in a bean bag.”Dorogi suggests something as simple as a yoga ball on a milk crate that allows your fidgety child to focus.“That is truly how their brain works and when we allow them to move and interact and talk that’s when they are going to learn,” she said.This story was originally reported by Syma Chowdhry at WXYZ. 2615

When the COVID-19 pandemic first prompted shelter-in-place restrictions, daycares across the country quickly saw families withdraw their children from their centers. Many lost valuable tuition dollars that keeps their doors open."We've done the best we can in staying open and supporting our community. We are a locally private-owned school so our enrollment really depends on the survival of the school and we’re struggling. I mean, as probably all childcare centers are, we’re struggling with enrollment, we’re struggling with our numbers," says Debbie Bradford, the director of education at Milton Montessori in Georgia.Bradford says the last few months have been very challenging as many families are worried about the coronavirus."The (coronavirus) numbers are on the rise so it’s definitely affecting the end of our school year, our summer and as we look to relaunch in August, we still see light enrollment," says Bradford.The school, which has two locations, has been able to stay open due to a number of parents who are essential workers. Bradford says, "These are front-line families. Some of them are workers on the front line and some of them are workers at home but need the income to make ends meet for our families."Primrose Schools has more than 400 locations across the country, providing infant daycare through private kindergarten. Primrose says the pandemic has dropped enrollment numbers at their facilities significantly."What we are seeing across the country is a very unsettling situation, where a lot of the family home cares that used to be accessible to families are closing. And the childcare centers, those individually owned and operated childcare centers, because of the shelter in place situation, many of them haven't been able to survive them," says Jo Kirchner, the CEO of Primrose Schools.Kirchner has been meeting regularly with other national daycare facilities and says many are concerned about the future of the childcare industry."It is a potential crisis that is going to escalate significantly in the next eight to 10 weeks as the districts decide what they're going to do," says Kirchner.One glimmer of hope is the boost of private kindergarten enrollment, which some parents have deemed a safer alternative than their local public school. Many hope private kindergarten enrollment can be kind of a saving grace for some private childcare centers."It will be somewhat of a saving grace in terms of bringing in base revenue to cover their fixed costs while we get through this pandemic and the families with the younger children will begin to come back,” Kirchner said.For Milton Montessori, the owners are hopeful they will be able to ride out this pandemic."We hope that at some point, families get comfortable with the new requirements for cleaning and for health and safety. And as things return to a normal, it's going to be a new normal," says Bradford.Bradford says they're hoping families start feeling safe enough to enroll their children and continue to support locally-owned childcare centers. 3055

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

When a hidden camera snapped a picture of Cross River gorillas including several infants in Nigeria this summer, conservationists were thrilled.This subspecies of gorilla is one of the most endangered, with only an estimated 300 individual animals believed to exist. They live along the border of Nigeria and Cameroon, in western Africa.The Wildlife Conservation Society captured images of the Cross River gorillas in Nigeria’s Mbe Mountains in May and June. Their camera traps have only captured images of Cross River gorillas a handful of times since being set up in 2012. They said this was the first time they had seen multiple infants in the same group. 666

来源：资阳报